[go: up one dir, main page]

WO1999037775A3 - Compositions and methods for detecting and treating breast cancer - Google Patents

Compositions and methods for detecting and treating breast cancer Download PDF

Info

Publication number
WO1999037775A3
WO1999037775A3 PCT/US1999/001556 US9901556W WO9937775A3 WO 1999037775 A3 WO1999037775 A3 WO 1999037775A3 US 9901556 W US9901556 W US 9901556W WO 9937775 A3 WO9937775 A3 WO 9937775A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
breast cancer
detecting
treating breast
Prior art date
Application number
PCT/US1999/001556
Other languages
French (fr)
Other versions
WO1999037775A2 (en
Inventor
Fei Huang
Jennifer R Adelman
Paul B Fisher
Neil I Goldstein
Original Assignee
Genquest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genquest Inc filed Critical Genquest Inc
Priority to AU23422/99A priority Critical patent/AU2342299A/en
Publication of WO1999037775A2 publication Critical patent/WO1999037775A2/en
Publication of WO1999037775A3 publication Critical patent/WO1999037775A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions and methods for the detection and therapy of breast cancer are disclosed. The compounds provided include tumor-associated proteins, and portions and variants thereof, as well as polynucleotides that encode such polypeptides. Vaccines and pharmaceutical compositions comprising such compounds are also provided and may be used, for example, for cancer prevention and treatment. The polypeptides may also be used for the production of antibodies, which are useful for diagnosing and monitoring cancer progression in a patient.
PCT/US1999/001556 1998-01-26 1999-01-25 Compositions and methods for detecting and treating breast cancer WO1999037775A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23422/99A AU2342299A (en) 1998-01-26 1999-01-25 Compositions and methods for detecting and treating breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7252698P 1998-01-26 1998-01-26
US60/072,526 1998-01-26

Publications (2)

Publication Number Publication Date
WO1999037775A2 WO1999037775A2 (en) 1999-07-29
WO1999037775A3 true WO1999037775A3 (en) 1999-11-04

Family

ID=22108171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001556 WO1999037775A2 (en) 1998-01-26 1999-01-25 Compositions and methods for detecting and treating breast cancer

Country Status (2)

Country Link
AU (1) AU2342299A (en)
WO (1) WO1999037775A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489101B1 (en) 1999-11-30 2002-12-03 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
WO2001040269A2 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
WO2001074859A2 (en) 2000-04-04 2001-10-11 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
EP1788085A1 (en) * 2000-04-04 2007-05-23 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU2006202984B2 (en) * 2000-04-04 2009-12-03 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
WO2002070695A2 (en) * 2001-03-05 2002-09-12 Mount Sinai Hospital Tumor associated proteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007522A1 (en) * 1992-09-30 1994-04-14 Yale University Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids
WO1994007474A1 (en) * 1992-09-30 1994-04-14 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
WO1995024205A1 (en) * 1994-03-07 1995-09-14 New York University Medical Center Methods and compositions for treatment of breast cancer
WO1996038463A1 (en) * 1995-05-31 1996-12-05 Washington University Dna sequence and encoded mammary-specific breast cancer protein
WO1997046884A1 (en) * 1996-06-05 1997-12-11 Matritech, Inc. Materials and methods for detection of breast cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007522A1 (en) * 1992-09-30 1994-04-14 Yale University Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids
WO1994007474A1 (en) * 1992-09-30 1994-04-14 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
WO1995024205A1 (en) * 1994-03-07 1995-09-14 New York University Medical Center Methods and compositions for treatment of breast cancer
WO1996038463A1 (en) * 1995-05-31 1996-12-05 Washington University Dna sequence and encoded mammary-specific breast cancer protein
WO1997046884A1 (en) * 1996-06-05 1997-12-11 Matritech, Inc. Materials and methods for detection of breast cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide

Also Published As

Publication number Publication date
WO1999037775A2 (en) 1999-07-29
AU2342299A (en) 1999-08-09

Similar Documents

Publication Publication Date Title
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
IL153996A0 (en) Polypeptides containing at least a portion of an ovarian carcinoma protein, polynucleotides encoding the same and pharmaceutical compositions containing the same
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2000036107A3 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
HUP0203035A2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2003087831A3 (en) Proteins involved in breast cancer
WO1997008318A3 (en) Compounds and methods for treatment and diagnosis of prostate cancer
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
WO1999037775A3 (en) Compositions and methods for detecting and treating breast cancer
WO2001079276A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000061753A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
WO1999054466A3 (en) Colon cancer-associated antigens and their diagnostic and therapeutic uses
WO1999037778A3 (en) Compositions and methods for detecting and treating prostate cancer
WO2002098359A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
AU2002365104A8 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
EP1422238A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase